Hypertrophic cardiomyopathy imposes a substantial economic and health burden, highlighting the need for more effective management approaches and potentially value-based care.
Despite advances in diagnosis and treatment, hypertrophic cardiomyopathy (HCM) continues to impose a substantial and growing burden on patients and health care systems.Historically recognized primarily for its association with sudden cardiac death in young individuals, the clinical paradigm of HCM has evolved.It is now understood as a complex, chronic disorder requiring lifelong management of progressive symptoms and recurrent hospitalizations.Definitive treatment strategies have largely focused on symptom relief through pharmacotherapy and septal reduction therapy (SRT) for obstructive disease.Given the profound implications for survival, quality of life, and health care costs, more effective management approaches are urgently needed.
Abughazaleh et al. (Fri,) studied this question.